A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy

L. Fredrik Jarskog, Martin T. Lowy, Richard A. Grove, Richard S.E. Keefe, Joseph P. Horrigan, M. Patricia Ball, Alan Breier, Robert W. Buchanan, Cameron S. Carter, John G. Csernansky, Donald C. Goff, Michael F. Green, Joshua T. Kantrowitz, Matcheri S. Keshavan, Marc Laurelle, Jeffrey A. Lieberman, Stephen R. Marder, Paul Maruff, Robert P. McMahon, Larry J. SeidmanMargaret A. Peykamian

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

This Phase II exploratory study assessed GSK239512, a brain penetrant histamine H<inf>3</inf> receptor antagonist, versus placebo on cognitive impairment in 50 stable outpatients with schizophrenia. Subjects were randomized to placebo or GSK239512 for 7weeks (4weeks titration). GSK239512 was associated with a small positive effect size (ES) on the CogState Schizophrenia Battery (CSSB) Composite Score (ES=0.29, CI=-0.40, 0.99) relative to placebo (primary endpoint). GSK239512's ES on CSSB domains were generally positive or neutral except Processing Speed, which favored placebo (ES=-0.46). Effects on the MATRICS Consensus Cognitive Battery were mostly neutral or favored placebo. GSK239512 was generally well tolerated with an adverse event profile consistent with the known class pharmacology. There was no evidence of overall beneficial effects of GSK239512 for CIAS in this population.

Original languageEnglish (US)
Pages (from-to)136-142
Number of pages7
JournalSchizophrenia Research
Volume164
Issue number1-3
DOIs
StatePublished - May 1 2015

    Fingerprint

Keywords

  • Cognition
  • CogState Schizophrenia Battery
  • GSK239512
  • Histamine H<inf>3</inf> antagonist
  • MATRICS Consensus Cognition Battery
  • Schizophrenia

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Biological Psychiatry

Cite this

Jarskog, L. F., Lowy, M. T., Grove, R. A., Keefe, R. S. E., Horrigan, J. P., Ball, M. P., Breier, A., Buchanan, R. W., Carter, C. S., Csernansky, J. G., Goff, D. C., Green, M. F., Kantrowitz, J. T., Keshavan, M. S., Laurelle, M., Lieberman, J. A., Marder, S. R., Maruff, P., McMahon, R. P., ... Peykamian, M. A. (2015). A Phase II study of a histamine H3 receptor antagonist GSK239512 for cognitive impairment in stable schizophrenia subjects on antipsychotic therapy. Schizophrenia Research, 164(1-3), 136-142. https://doi.org/10.1016/j.schres.2015.01.041